Application No. 09/441,411
Reply to Office Action dated November 4, 2002

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-8 (canceled).

Claim 9 (currently amended): A composition for eliciting or enhancing the titer of antibodies specific for a cell surface receptor antigen, comprising a recombinant expression construct comprising at least one promoter operably linked to a nucleic acid sequence encoding a cell surface receptor antigen, a nucleic acid sequence encoding a first immune response altering molecule and a nucleic acid sequence encoding a second immune response altering molecule, according to any one of claims 1-8 wherein the cell surface receptor antigen is Her2/Neu, the first immune response altering molecule is 4-1BB ligand, and the second immune response altering molecule is CD86/B7.2.

Claim 10 (currently amended): The composition of <u>any one of claims 9 and 12-14</u>, wherein Her2/Neu comprises a polypeptide sequence selected from the group consisting of sequences set forth in GenBank Acc. Nos. X03363 (<u>as set forth in SEQ ID NO: 6</u>), M17730 (<u>as set forth in SEQ ID NO: 8</u>), and SEG_HUMHER20 (<u>as set forth in SEQ ID NO: 9</u>).

Claim 11 (currently amended): The composition of <u>any one of claims 9 and 12-14</u>, wherein CD86/B7.2 comprises a polypeptide sequence selected from the group consisting of sequences set forth in GenBank Acc. Nos. AF099105, SEG_MMB72G (<u>as set forth in SEQ ID NOS: 11-15</u>), U39466 (<u>as set forth in SEQ ID NOS: 16-20</u>), U04343 (<u>as set forth in SEQ ID NO: 22</u>), SEG_HSB725, L25606 (<u>as set forth in SEQ ID NO: 24</u>), and L25259 (<u>as set forth in SEQ ID NO: 26</u>).

2

Application No. 09/441,411 Reply to Office Action dated November 4, 2002

Claim 12 (new): A composition for eliciting or enhancing the titer of antibodies specific for a cell surface receptor antigen, comprising:

- a) a first recombinant expression construct containing at least one promoter operably linked to a nucleic acid sequence encoding a cell surface receptor antigen and a nucleic acid sequence encoding a first immune response altering molecule; and
- b) a second recombinant expression construct containing a promoter operably linked to a nucleic acid sequence encoding a second immune response altering molecule,

wherein the cell surface receptor antigen is Her2/Neu, the first immune response altering molecule is 4-1BB ligand, and the second immune response altering molecule is CD86/B7.2.

Claim 13 (new): A composition for eliciting or enhancing the titer of antibodies specific for a cell surface receptor antigen, comprising:

- a) a first recombinant expression construct containing at least one promoter operably linked to a nucleic acid sequence encoding a cell surface receptor antigen;
- b) a second recombinant expression construct containing a promoter operably linked to a nucleic acid sequence encoding a first immune response altering molecule; and
- c) a third recombinant expression construct containing a promoter operably linked to a nucleic acid sequence encoding a second immune response altering molecule,

wherein the cell surface receptor antigen is Her2/Neu, the first immune response altering molecule is 4-1BB ligand, and the second immune response altering molecule is CD86/B7.2.

Claim 14 (new): A composition for eliciting or enhancing the titer of antibodies specific for a cell surface receptor antigen, comprising:

a) a first recombinant expression construct containing at least one promoter operably linked to a nucleic acid sequence encoding a cell surface receptor antigen; and

Application No. 09/441,411
Reply to Office Action dated November 4, 2002

b) a second recombinant expression construct containing at least one promoter operably linked to a nucleic acid sequence encoding a first immune response altering molecule and a nucleic acid sequence encoding a second immune response altering molecule,

wherein the cell surface receptor antigen is Her2/Neu, the first immune response altering molecule is 4-1BB ligand, and the second immune response altering molecule is CD86/B7.2.

Claim 15 (new): A composition for eliciting or enhancing the titer of antibodies specific for a cell surface receptor antigen, comprising expression products of the recombinant expression constructs which comprise the composition according to any one of claims 9 and 12-14.